Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GILD
GILD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GILD News
WHO Approves Evaluation of Regeneron's Antibody for Ebola Treatment
1d ago
seekingalpha
New Findings on Livdelzi in PBC Treatment
3d ago
Newsfilter
Gilead Acquires Tubulis for $3.15B to Enhance Oncology Portfolio
4d ago
Yahoo Finance
U.S. Stocks Rise as Hopes for Iran Peace Deal Increase
May 22 2026
stocktwits
Gilead Secures Accelerated Approval for Hepcludex
May 22 2026
stocktwits
Gilead Receives FDA Approval for Chronic HDV Treatment
May 22 2026
Newsfilter
FDA Approves Gilead's Hepcludex for HDV Infection
May 22 2026
seekingalpha
WHO Raises Ebola Outbreak Risk Level in DRC to Very High
May 22 2026
Newsfilter
Trodelvy Recommended for First-Line Treatment in Europe
May 22 2026
NASDAQ.COM
Gilead Completes Acquisition of Tubulis to Enhance Oncology Leadership
May 21 2026
Newsfilter
Gilead Renews Five-Year Collaboration with WHO to Combat Visceral Leishmaniasis
May 21 2026
Newsfilter
Volatility in UK Assets Amid Political Turmoil and Investment Opportunities
May 21 2026
CNBC
Latest Wall Street Rating Updates
May 20 2026
CNBC
Analysis of IBB ETF Trading Dynamics
May 19 2026
NASDAQ.COM
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
May 15 2026
CNBC
Gilead Sciences Prices $3 Billion Senior Notes Offering
May 15 2026
seekingalpha
Show More News
